Valter Torri
Istituto Di Ricerche Farmacologiche Mario Negri · Mario Negri Institute for Pharmacological Research Milano (Italy)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Valter Torri as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04765709 · Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCMario Negri Institute for Pharmacological Research · terminated · Non-small Cell Lung Cancer Stage III · study chair
- Ph2NCT03358017 · Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast CancerMario Negri Institute for Pharmacological Research · completed · Triple Negative Breast Cancer · study chair
- Ph2NCT02194231 · ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)Mario Negri Institute for Pharmacological Research · completed · Malignant Pleural Mesothelioma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 09:51 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.J Natl Cancer Inst · 2003464 citationsRCR 9.7
- 417 citationsRCR 11.0
- Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.J Clin Oncol · 2012223 citationsRCR 5.6
- 139 citationsRCR 3.8
- 90 citationsRCR 2.0
- 71 citationsRCR 2.8
- SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.J Proteomics · 201264 citationsRCR 1.8
- 49 citationsRCR 1.6
- Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.Ann Oncol · 201544 citationsRCR 1.1
- PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.J Immunother Cancer · 202320 citationsRCR 1.5